Patents by Inventor Shin Ae SEO

Shin Ae SEO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition for inducing cell reprogramming
    Patent number: 10858321
    Abstract: The present invention relates to a composition for inducing cell reprogramming. The indazole derivative compound contained in the composition of the present invention shows an improved biological profile and at the same time can perform efficient cell reprogramming. In addition, unlike conventional compounds (e.g. riversine or BIO) for inducing low-molecular cell reprogramming, the indazole derivative compound of the present invention does not show cytotoxicity and thus is expected to have high growth in the market of cell therapy products when clinically applied. Conventional indazole derivative compounds have never known as a use for cell reprogramming. Compared with conventional indazole derivative compounds, the compound of the present invention has a great cell reprogramming ability while having no or little cytotoxicity.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: December 8, 2020
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Yong Chul Kim, Darren R. Williams, Da Woon Jung, Jung Eun Lee, Shin Ae Seo, Ji Yeon Park
  • COMPOSITION FOR INDUCING CELL REPROGRAMMING
    Publication number: 20170158642
    Abstract: The present invention relates to a composition for inducing cell reprogramming. The indazole derivative compound contained in the composition of the present invention shows an improved biological profile and at the same time can perform efficient cell reprogramming. In addition, unlike conventional compounds (e.g. riversine or BIO) for inducing low-molecular cell reprogramming, the indazole derivative compound of the present invention does not show cytotoxicity and thus is expected to have high growth in the market of cell therapy products when clinically applied. Conventional indazole derivative compounds have never known as a use for cell reprogramming. Compared with conventional indazole derivative compounds, the compound of the present invention has a great cell reprogramming ability while having no or little cytotoxicity.
    Type: Application
    Filed: June 30, 2015
    Publication date: June 8, 2017
    Inventors: Yong Chul KIM, Darren R. Williams, Da Woon JUNG, Jung Eun LEE, Shin Ae SEO, Ji Yeon PARK